Kiniksa Pharmaceuticals International, plc
KNSAKiniksa Pharmaceuticals International, plc's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (67 weeks in). Underneath, the last four quarters read improving — profit +100.0% year on year, and 64% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Kiniksa Pharmaceuticals International, plc trades at $76.0, in a confirmed uptrend and 67 weeks into that stage. That is +57.2% against its own 200-day average. It sits at 100% of a 52-week range of $33 to $76. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is in a confirmed uptrend — week 67 of stage 2. At $76.0 it trades +57.2% versus its 200-day average and sits at 100% of its 52-week range ($33–$76).
Against the market, two honest reads. Cumulative: over the last 8.2 years the stock moved +291% while the S&P 500 moved +183% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Kiniksa Pharmaceuticals International, plc trades at 76.7× P/E, against too little history to rank. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 76.7× is against too little history to rank. This is a comparison against the stock's own history — not a claim about what it is worth.
The price move, decomposed: over 3y, of the +60.7%/yr price move, ~−35.0%/yr came from earnings growth and ~+95.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Kiniksa Pharmaceuticals International, plc reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +61.9% | +45.7% | — | — |
| Profit | — | −30.7% | — | — |
| EPS | — | −33.9% | — | — |
| Stock price | +137.6% | +60.7% | +42.1% | — |
4-Factor Sector Score
59.2/100 — rank 4 of 28 in Drug Manufacturers - Specialty & Generic · 58% evidence confidence
Kiniksa Pharmaceuticals International, plc scores 59.2 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 4. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 19.3 + 12 + 9.1 + 18.8 = 59.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Kiniksa Pharmaceuticals International, plc reported $0.2 B of revenue in the Mar 26 quarter, +50.0% year on year. That is the 10th straight quarter of year-on-year growth. Over 4 years it has compounded at 103.1% a year. The last full year, FY25, came in at $0.7 B. The last four reported quarters add to $0.8 B.
FY25 revenue came in at $0.7 B (+61.9% on the year), capping 4 years at 103.1% compound. The latest quarter (Mar 26) printed $0.2 B, +50.0% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +56.5% growth against the decade's 103.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +56.3% over the last 4 quarters against +58.1%/yr over the last 8 — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Kiniksa Pharmaceuticals International, plc's operating margin is 14.3% in the Mar 26 quarter, +7.2 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged −400.0% to 11.8%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 14.3%, +7.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −400.0%–11.8%, and FY25's 11.8% is the top of that band — a record year.
Why the margin moved: operating margin went +7.2 pp year on year while gross margin went +4.8 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Kiniksa Pharmaceuticals International, plc earned $0.0 B of net profit in the Mar 26 quarter, +100.0% year on year. Full-year FY25 profit was $0.1 B. That is 9.5% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 4 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.0 B, +100.0% year on year. On the full year, FY25 printed $0.1 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 64% of Kiniksa Pharmaceuticals International, plc's reported profit arrived as operating cash — most of the profit is real cash. In FY25 that was $0.1 B of operating cash against $0.1 B of profit. After $0.0 B of capital spending, $0.1 B was left as free cash.
FY25: operating cash of $0.1 B against reported profit of $0.1 B, leaving free cash of $0.1 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 64% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Kiniksa Pharmaceuticals International, plc does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Kiniksa Pharmaceuticals International, plc earns a ROE of 11% in FY25. That is up from a trough of −84% in FY21. Return on invested capital clears the cost of that capital by +45.3 percentage points, so growth here adds value rather than only size. The wiring behind it is 8.8% net margin on 0.89× asset turns.
FY25 ROE is 11%, recovered from a FY21 trough of −84% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 8.8% net margin × 0.89× asset turns × 1.33× balance-sheet leverage ≈ 10.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 49.9% − 4.6% = a +45.3 pp spread. The 4.6% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
Kiniksa Pharmaceuticals International, plc pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Kiniksa Pharmaceuticals International, plc does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Kiniksa Pharmaceuticals International, plc carries total debt of $0.0 B against shareholder equity of $0.7 B as of Jun 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.05 in FY21 to 0.02 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of $0.0 B against shareholder equity of $0.7 B — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.05 (FY21) to 0.02 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
10.2% of Kiniksa Pharmaceuticals International, plc's tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 4.3 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 10.2% of the float is sold short, and at typical trading volumes it would take about 4.3 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Kiniksa Pharmaceuticals International, plc: the Z-score reads 9.23. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 9.23 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 9.23.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Liquidia CorporationLQDA | 72.3/100Favorable setup64% evidence | LEADER | 25.7/35 Revenue 100% · PAT — · OPM change 1181.7 pp 62% evidence | 18.0/25 ROCE 29.4% · OPM 46.3% 76% evidence | 8.6/20 P/E 269.6× · PEG — 15% evidence | 20.0/20 RS sector 86.6% · RS bench 89.6% · 1Y 332.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 25.7 + 18 + 8.6 + 20 = 72.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Indivior Pharmaceuticals, Inc.INDV | 63.8/100Mixed-positive evidence64% evidence | FADING | 24.0/35 Revenue 10.3% · PAT — · OPM change 18.4 pp 62% evidence | 21.0/25 ROCE 34.8% · OPM 43.2% 76% evidence | 11.4/20 P/E 3.1× · PEG — 15% evidence | 7.4/20 RS sector -1.2% · RS bench 0.8% · 1Y 65.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 21 + 11.4 + 7.4 = 63.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Amneal Pharmaceuticals, Inc.AMRX | 60.6/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 5.2 pp 45% evidence | 13.3/25 ROCE 5% · OPM 19.6% 76% evidence | 9.8/20 P/E 35.3× · PEG — 15% evidence | 17.9/20 RS sector 26.4% · RS bench 28.8% · 1Y 116.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 13.3 + 9.8 + 17.9 = 60.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Kiniksa Pharmaceuticals International, plcthis pageKNSA | 59.2/100Thin evidence · provisional58% evidence | BREAKING OUT | 19.3/35 Revenue — · PAT — · OPM change 4.1 pp 45% evidence | 12.0/25 ROCE 4.3% · OPM 13.7% 76% evidence | 9.1/20 P/E 101.5× · PEG — 15% evidence | 18.8/20 RS sector 45.1% · RS bench 47.9% · 1Y 136.4%7 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 12 + 9.1 + 18.8 = 59.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Lantheus Holdings, Inc.LNTH | 58.0/100Mixed-positive evidence81% evidence | FADING | 13.6/35 Revenue 0.6% · PAT 9.8% · OPM change -5.8 pp 83% evidence | 14.1/25 ROCE 4.3% · OPM 21.6% 76% evidence | 14.3/20 P/E 18.3× · PEG 1.02 65% evidence | 16.0/20 RS sector 20% · RS bench 22.2% · 1Y 76.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 13.6 + 14.1 + 14.3 + 16 = 58 · Decision use: Price leads the evidence: RS versus the benchmark is 22.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Neurocrine Biosciences, Inc.NBIX | 56.7/100Thin evidence · provisional58% evidence | FADING | 19.5/35 Revenue — · PAT — · OPM change 19.6 pp 45% evidence | 14.0/25 ROCE 3.9% · OPM 23.7% 76% evidence | 10.0/20 P/E 24.7× · PEG — 15% evidence | 13.2/20 RS sector 0.5% · RS bench 2.9% · 1Y 32.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 14 + 10 + 13.2 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Phibro Animal Health CorporationPAHC | 55.9/100Mixed-positive evidence75% evidence | ASLEEP | 25.5/35 Revenue 26.1% · PAT 100% · OPM change 2 pp 83% evidence | 13.3/25 ROCE 4% · OPM 11.6% 76% evidence | 12.1/20 P/E 23.7× · PEG 1.31 65% evidence | 5.0/20 RS sector -22.4% · RS bench -20.8% · 1Y 30.2%0 of 12 weeks ahead 70% evidence |
| Exact sum: 25.5 + 13.3 + 12.1 + 5 = 55.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -22.4% and the one-year return is 30.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 8Xeris Biopharma Holdings, Inc.XERS | 53.7/100Thin evidence · provisional58% evidence | BREAKING OUT | 24.5/35 Revenue 41.9% · PAT — · OPM change 14.6 pp 62% evidence | 8.8/25 ROCE 3.2% · OPM 9.5% 76% evidence | 9.3/20 P/E 96.7× · PEG — 15% evidence | 11.1/20 RS sector -0.7% · RS bench 1.7% · 1Y 19.7%9 of 12 weeks ahead 70% evidence |
| Exact sum: 24.5 + 8.8 + 9.3 + 11.1 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Haleon plcHLN | 52.6/100Thin evidence · provisional56% evidence | TURNING | 20.2/35 Revenue — · PAT — · OPM change 9.1 pp 39% evidence | 13.3/25 ROCE 2.2% · OPM 21.8% 76% evidence | 10.8/20 P/E 19.3× · PEG — 15% evidence | 8.3/20 RS sector -11.9% · RS bench -10% · 1Y 2.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.2 + 13.3 + 10.8 + 8.3 = 52.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Viatris Inc.VTRS | 51.2/100Mixed-positive evidence64% evidence | FADING | 21.8/35 Revenue 1.6% · PAT — · OPM change 86.3 pp 62% evidence | 7.7/25 ROCE -0.3% · OPM -2.3% 76% evidence | 8.7/20 P/E 216.6× · PEG — 15% evidence | 13.0/20 RS sector 17.5% · RS bench 19.7% · 1Y 82.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 7.7 + 8.7 + 13 = 51.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Trulieve Cannabis Corp.TRLV | 50.1/100Mixed-positive evidence64% evidence | FADING | 16.3/35 Revenue -1.4% · PAT — · OPM change 0.6 pp 62% evidence | 11.7/25 ROCE 5.6% · OPM 12.4% 76% evidence | 11.5/20 P/E -13.3× · PEG — 15% evidence | 10.6/20 RS sector 1% · RS bench 3.3% · 1Y 55.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 11.7 + 11.5 + 10.6 = 50.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12ANI Pharmaceuticals, Inc.ANIP | 48.8/100Mixed-negative evidence64% evidence | ASLEEP | 22.5/35 Revenue 36.9% · PAT — · OPM change 3.1 pp 62% evidence | 11.4/25 ROCE 3.4% · OPM 16.4% 76% evidence | 10.6/20 P/E 19.5× · PEG — 15% evidence | 4.3/20 RS sector -16.5% · RS bench -14.4% · 1Y -2.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 11.4 + 10.6 + 4.3 = 48.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Alkermes plcALKS | 48.4/100Thin evidence · provisional58% evidence | LEADER | 12.4/35 Revenue — · PAT — · OPM change -16.8 pp 45% evidence | 8.3/25 ROCE 0.7% · OPM -12.3% 76% evidence | 8.9/20 P/E 132.8× · PEG — 15% evidence | 18.8/20 RS sector 26.8% · RS bench 29.3% · 1Y 86%12 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 8.3 + 8.9 + 18.8 = 48.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Teva Pharmaceutical Industries LimitedTEVA | 47.3/100Thin evidence · provisional58% evidence | ASLEEP | 16.5/35 Revenue — · PAT — · OPM change 4.2 pp 45% evidence | 9.3/25 ROCE -0.9% · OPM 33.7% 76% evidence | 9.5/20 P/E 56.5× · PEG — 15% evidence | 12.0/20 RS sector 6.2% · RS bench 8.1% · 1Y 110.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 9.3 + 9.5 + 12 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Zoetis Inc.ZTS | 45.8/100Mixed-negative evidence81% evidence | BASING | 15.2/35 Revenue 2.6% · PAT 5.8% · OPM change -1.5 pp 83% evidence | 17.1/25 ROCE 6.7% · OPM 35.4% 76% evidence | 8.9/20 P/E 19.6× · PEG 2.03 65% evidence | 4.6/20 RS sector -43.3% · RS bench -41.9% · 1Y -48.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 17.1 + 8.9 + 4.6 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Bausch Health Companies Inc.BHC | 44.9/100Thin evidence · provisional58% evidence | TURNING | 16.0/35 Revenue — · PAT — · OPM change -49.8 pp 45% evidence | 8.9/25 ROCE 3.5% · OPM -37.6% 76% evidence | 11.0/20 P/E 16.5× · PEG — 15% evidence | 9.0/20 RS sector -7.7% · RS bench -5.4% · 1Y 12%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16 + 8.9 + 11 + 9 = 44.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Elanco Animal Health IncorporatedELAN | 43.3/100Mixed-negative evidence71% evidence | TURNING | 15.9/35 Revenue 10.5% · PAT -164.9% · OPM change 2.1 pp 83% evidence | 8.8/25 ROCE 1.2% · OPM 10.5% 76% evidence | 8.5/20 P/E 335.7× · PEG — 15% evidence | 10.1/20 RS sector -0.5% · RS bench 1.5% · 1Y 53.6%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 8.8 + 8.5 + 10.1 = 43.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18United Therapeutics CorporationUTHR | 42.7/100Mixed-negative evidence81% evidence | ASLEEP | 15.0/35 Revenue 5.9% · PAT 6.5% · OPM change -6.5 pp 83% evidence | 16.5/25 ROCE 5% · OPM 41.7% 76% evidence | 6.3/20 P/E 21.9× · PEG 2.7 65% evidence | 4.9/20 RS sector -6.7% · RS bench -4.8% · 1Y 72.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 16.5 + 6.3 + 4.9 = 42.7 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 19Prestige Consumer Healthcare Inc.PBH | 42.6/100Mixed-negative evidence71% evidence | BASING | 11.6/35 Revenue -4.3% · PAT -11.2% · OPM change -3 pp 83% evidence | 13.5/25 ROCE 2.3% · OPM 26.8% 76% evidence | 11.1/20 P/E 15.2× · PEG — 15% evidence | 6.4/20 RS sector -22.9% · RS bench -21.1% · 1Y -20.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 13.5 + 11.1 + 6.4 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Supernus Pharmaceuticals, Inc.SUPN | 40.7/100Mixed-negative evidence64% evidence | ASLEEP | 20.1/35 Revenue 16.3% · PAT -147.5% · OPM change 2.8 pp 62% evidence | 7.6/25 ROCE -0.8% · OPM -4% 76% evidence | 9.9/20 P/E 27.4× · PEG — 15% evidence | 3.1/20 RS sector -21.5% · RS bench -19.7% · 1Y 4.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 7.6 + 9.9 + 3.1 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21BioCryst Pharmaceuticals, Inc.BCRX | 37.2/100Thin evidence · provisional53% evidence | TURNING | 12.0/35 Revenue — · PAT — · OPM change -463.2 pp 32% evidence | 3.3/25 ROCE -230.1% · OPM -448.6% 76% evidence | 11.3/20 P/E 6.4× · PEG — 15% evidence | 10.6/20 RS sector -2.8% · RS bench -0.7% · 1Y 8.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 3.3 + 11.3 + 10.6 = 37.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Hims & Hers Health, Inc.HIMS | 34.5/100Adverse evidence71% evidence | TURNING | 11.2/35 Revenue 32.8% · PAT -107.3% · OPM change -22.8 pp 83% evidence | 5.7/25 ROCE -6.9% · OPM -12.9% 76% evidence | 9.4/20 P/E 63.7× · PEG — 15% evidence | 8.2/20 RS sector -17.4% · RS bench -14.8% · 1Y -38.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 5.7 + 9.4 + 8.2 = 34.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Harrow, Inc.HROW | 34.4/100Thin evidence · provisional55% evidence | ASLEEP | 13.5/35 Revenue 26.3% · PAT — · OPM change -26.5 pp 62% evidence | 4.5/25 ROCE -8.7% · OPM -50% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.4/20 RS sector -14.8% · RS bench -12.9% · 1Y 15.7%5 of 12 weeks ahead 70% evidence |
| Exact sum: 13.5 + 4.5 + 10 + 6.4 = 34.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24AlvotechALVO | 31.2/100Adverse evidence65% evidence | TURNING | 9.6/35 Revenue -4.4% · PAT -183.5% · OPM change 1.1 pp 83% evidence | 8.0/25 ROCE 0.9% · OPM 9.1% 76% evidence | 9.6/20 P/E 51.3× · PEG — 15% evidence | 4.0/20 RS sector -35.5% · RS bench -33.4% · 1Y -54.6%3 of 12 weeks ahead 70% evidence |
| Exact sum: 9.6 + 8 + 9.6 + 4 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Perrigo Company plcPRGO | 27.0/100Thin evidence · provisional55% evidence | BASING | 8.3/35 Revenue -3.6% · PAT — · OPM change -42.9 pp 62% evidence | 5.0/25 ROCE -4.8% · OPM -38.4% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.7/20 RS sector -35.5% · RS bench -33.6% · 1Y -52.2%1 of 12 weeks ahead 70% evidence |
| Exact sum: 8.3 + 5 + 10 + 3.7 = 27 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Amylyx Pharmaceuticals, Inc.AMLX | 52.7/100Thin evidence · provisional43% evidence | TURNING | 17.3/35 Revenue — · PAT — · OPM change 6111.6 pp 13% evidence | 6.0/25 ROCE -18.3% · OPM — 61% evidence | 10.4/20 P/E 21× · PEG — 15% evidence | 19.0/20 RS sector 34.5% · RS bench 37.1% · 1Y 186.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 6 + 10.4 + 19 = 52.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27HUTCHMED (China) LimitedHCM | 38.1/100Thin evidence · provisional43% evidence | BASING | 17.3/35 Revenue — · PAT — · OPM change — 12% evidence | 8.2/25 ROCE 0% · OPM — 61% evidence | 9.0/20 P/E 107.6× · PEG — 15% evidence | 3.6/20 RS sector -27.8% · RS bench -26% · 1Y -22.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 8.2 + 9 + 3.6 = 38.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Regencell Bioscience Holdings LimitedRGC | 30.4/100Thin evidence · provisional40% evidence | BASING | 13.4/35 Revenue — · PAT — · OPM change — 24% evidence | 7.0/25 ROCE -60.5% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.0/20 RS sector -72.7% · RS bench -72.3% · 1Y -56.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 7 + 10 + 0 = 30.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Kiniksa Pharmaceuticals International, plc's stock price today?
Kiniksa Pharmaceuticals International, plc trades at $76.0, +137.6% over the past year. The company is valued at $6.0 B. The stock sits at 100% of its 52-week range of $33–$76, +57.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 67 weeks in. — as of 5 August 2026.
What were Kiniksa Pharmaceuticals International, plc's latest quarterly results?
Kiniksa Pharmaceuticals International, plc reported revenue of $0.2 B and net profit of $0.0 B for the Mar 26 quarter. Revenue rose 50.0% and profit rose 100.0% year on year. Earnings per share were $0.27. The operating margin was 14.3%, 7.2 pp higher than a year earlier. — as of 5 August 2026.
What is Kiniksa Pharmaceuticals International, plc's revenue?
Kiniksa Pharmaceuticals International, plc reported revenue of $0.2 B in the Mar 26 quarter, +50.0% year on year. For the full FY25 fiscal year, revenue was $0.7 B (+61.9%). Over the last 4 years revenue compounded at 103.1% a year. — as of 5 August 2026.
What is Kiniksa Pharmaceuticals International, plc's profit?
Kiniksa Pharmaceuticals International, plc earned $0.0 B of net profit in the Mar 26 quarter, +100.0% year on year. Full-year FY25 profit was $0.1 B. The operating margin ran 14.3% in the latest quarter. — as of 5 August 2026.
What is Kiniksa Pharmaceuticals International, plc's market cap?
Kiniksa Pharmaceuticals International, plc's market capitalisation is $6.0 B at a stock price of $76.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Kiniksa Pharmaceuticals International, plc pay a dividend?
No — Kiniksa Pharmaceuticals International, plc has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
Is Kiniksa Pharmaceuticals International, plc growing?
Yes — Kiniksa Pharmaceuticals International, plc is growing: latest-quarter revenue +50.0% year on year, profit +100.0%, and the margin +7.2 pp at 14.3%. The earnings engine currently reads: improving — as of 5 August 2026.
How is Kiniksa Pharmaceuticals International, plc performing?
Kiniksa Pharmaceuticals International, plc is in a confirmed uptrend, 67 weeks in. Its latest quarter's revenue rose 50.0% and profit rose 100.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 5 August 2026.
Is Kiniksa Pharmaceuticals International, plc in an uptrend?
Yes — the price is in a confirmed uptrend (week 67 of stage 2), trading +57.2% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Kiniksa Pharmaceuticals International, plc beating the market?
On recent form, yes — Kiniksa Pharmaceuticals International, plc has been ahead of the S&P 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 8.2 years the stock moved +291% against the S&P 500's +183% — ahead of the index over the full window. — as of 5 August 2026.
Will Kiniksa Pharmaceuticals International, plc's stock price go up?
This page publishes no price forecast for Kiniksa Pharmaceuticals International, plc. What it measures instead: the stock price is $76.0, the price is in a confirmed uptrend 67 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Kiniksa Pharmaceuticals International, plc?
Yes — short interest is 10.2% of Kiniksa Pharmaceuticals International, plc's tradable float, about 4.3 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Kiniksa Pharmaceuticals International, plc have too much debt?
No — Kiniksa Pharmaceuticals International, plc's debt-to-equity is 0.01. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.
What is Kiniksa Pharmaceuticals International, plc's capex?
Kiniksa Pharmaceuticals International, plc spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Kiniksa Pharmaceuticals International, plc's cash flow?
Kiniksa Pharmaceuticals International, plc generated $0.1 B of operating cash flow in FY25 and $0.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Kiniksa Pharmaceuticals International, plc's profit real cash?
Mostly — over the last 3 fiscal years, 64% of Kiniksa Pharmaceuticals International, plc's reported profit arrived as operating cash. In FY25, operating cash was $0.1 B against reported profit of $0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Kiniksa Pharmaceuticals International, plc?
On the balance sheet, the Z-score reads 9.23 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Kiniksa Pharmaceuticals International, plc in its business cycle?
Kiniksa Pharmaceuticals International, plc's FY25 operating margin was 11.8%, against a 5-year band of −400.0%–11.8%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 14.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Kiniksa Pharmaceuticals International, plc story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Kiniksa Pharmaceuticals International, plc a stock worth studying right now?
This is not investment advice. The machine read: Kiniksa Pharmaceuticals International, plc's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.